Ad copy

By mid-2026, retatrutide is a known entity. Eli Lilly's triple GLP-1/ GIP/glucagon agonist has now completed all four core TRIUMPH phase 3 trials plus a diabetes-focused TRANSCEND trial, and the data is astounding: up to roughly 28%-30% average body weight loss at the highest doses; significant improvements in cholesterol, blood pressure, sleep apnea severity, and knee osteoarthritis pain; and a safety profile that looks similar to semaglutide and tirzepatide. Lilly is expected to file for FDA approval in the first quarter of 2027. For patients with severe, treatment-resistant obesity and life-threatening comorbidities right now, the expanded access program is supposed to help. In practice, the retatrutide expanded access pathway is more of an obstacle than it is a bridge, which potentially pits the doctor against the patient. Read the full commentary by tapping the link in our bio.